Celldex: Can It Succeed Just Once?

  • Celldex has had multiple failures before.
  • However, its glembatumumab vedotin is yielding some decent results in metastatic melanoma and triple negative breast cancer.
  • Down near its 52-week lows, this may be a good catalyst-driven investment, even if you worry about its history of failures.

By Dr. Udaya K Maiya, MBBS, MD, DNB, DCCF - Paris

At this year’s just-concluded ASCO conference held at the McCormick Place in Chicago overlooking Lake Michigan, Celldex (NASDAQ:CLDX) reported good results from its metastatic melanoma study of glembatumumab vedotin, a fully-human monoclonal antibody-drug conjugate (ADC) that targets glycoprotein NMB (gpNMB).

The full post is available to investor members only. Subscribe here.